The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Prospective Evaluation of Cancer Clinical Trial Accrual Patterns: Identifying Potential Barriers to Enrollment
Abstract
PURPOSE: Well-conducted cancer clinical trials are essential for improving patient outcomes. Unfortunately, only 3% of new cancer patients participate in clinical trials. Barriers to patient accrual in cancer clinical trials must be identified and overcome to increase patient participation. MATERIALS AND METHODS: We prospectively tracked factors that potentially affected patient accrual into cancer clinical trials at the University of California Davis Cancer Center. Oncologists seeing new outpatients were asked to complete questionnaires regarding patient characteristics and the physician’s decision-making on patient eligibility, protocol availability, and patient opinions on participation. Statistical analysis was performed to correlate these parameters with subsequent protocol accrual. RESULTS: There were 276 assessable patients. At the initial visits, physicians did not consider clinical trials in 38% (105/276) of patients principally because of a perception of protocol unavailability and poor performance status. Physicians considered 62% (171/276) of patients for participation in clinical trials. Of these, only 53% (91/171) had an appropriate protocol available for site and stage of disease. Seventy-six of 90 patients (84%) with available protocols met eligibility criteria for a particular study. Only 39 of 76 patients (51%) agreed to participate in cancer clinical trials, for an overall accrual rate of 14% (39/276). The remainder (37/76, 49%) declined trial participation despite meeting eligibility criteria. The most common reasons were a desire for other treatment (34%), distance from the cancer center (13%), patient refusal to disclose reason (11%), and insurance denial (8%). Patients with private insurance were less likely to enroll in clinical trials compared to those with government-funded insurance (OR, 0.34; P = .03; 95% CI, 0.13 to 0.9). CONCLUSION: Barriers to cancer clinical trial accrual can be prospectively identified and addressed in the development and conduct of future studies, which may potentially lead to more robust clinical trials enrollment. Investigation of patient perceptions regarding the clinical trials process and the role of third party–payers is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
Representation of older patients in cancer treatment trials
Trimble, E. L., Cain, D., Ungerleider, R. S., Friedman, M. A., Carter, C. L., & Freidlin, B. (1994) · Cancer · doi:10.1002/1097-0142(19941001)74:7+<2208::aid-cncr2820741737>3.0.co;2-# · Cited by 343
Tejeda, H. A., Green, S. B., Trimble, E. L., Ford, L., High, J. L., Ungerleider, R. S., Friedman, M. A., & Brawley, O. W. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.12.812 · Cited by 269
Centralised treatment, entry to trials and survival
Stiller, C. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.306 · Cited by 247
Strategic Physician Communication and Oncology Clinical Trials
Albrecht, T. L., Blanchard, C., Ruckdeschel, J. C., Coovert, M., & Strongbow, R. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3324 · Cited by 160
Kaluzny, A. D., Brawley, O. W., Garson-Angert, D., Shaw, J. R., Godley, P. A., Warnecke, R. B., & Ford, L. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.23.1945 · Cited by 82
A Study in Contrasts: Eligibility Criteria in a Twenty-Year Sample of NSABP and POG Clinical Trials
Fuks, A., Weijer, C., Freedman, B., Shapiro, S. H., Skrutkowska, M., & Riaz, A. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00240-0 · Cited by 78
Ellis, P. M., Butow, P. N., Simes, R. J., Tattersall, M. H. N., & Dunn, S. M. (1999) · Australian and New Zealand Journal of Surgery · doi:10.1046/j.1440-1622.1999.01608.x · Cited by 54
Cited by
Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review
Ford, J. G., Howerton, M. W., Lai, G. Y., Gary, T. L., Bolen, S., Gibbons, M. C., Tilburt, J., Baffi, C., Tanpitukpongse, T. P., Wilson, R. F., et al. (2008) · Cancer · doi:10.1002/cncr.23157 · Cited by 1,083
Talarico, L., Chen, G., & Pazdur, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.175 · Cited by 727
The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies
Unger, J. M., Cook, E., Tai, E., & Bleyer, A. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_156686 · Cited by 665
Systematic Review of Barriers to the Recruitment of Older Patients With Cancer Onto Clinical Trials
Townsley, C. A., Selby, R., & Siu, L. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.141 · Cited by 583
Unger, J. M., Vaidya, R., Hershman, D. L., Minasian, L. M., & Fleury, M. E. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy221 · Cited by 570
Mills, E. J., Seely, D., Rachlis, B., Griffith, L., Wu, P., Wilson, K., Ellis, P., & Wright, J. R. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70576-9 · Cited by 536
Peppercorn, J. M., Smith, T. J., Helft, P. R., DeBono, D. J., Berry, S. R., Wollins, D. S., Hayes, D. M., Von Roenn, J. H., & Schnipper, L. E. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.1744 · Cited by 524
Sedrak, M. S., Freedman, R. A., Cohen, H. J., Muss, H. B., Jatoi, A., Klepin, H. D., Wildes, T. M., Le‐Rademacher, J. G., Kimmick, G. G., Tew, W. P., et al. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21638 · Cited by 471
Barriers to Clinical Trial Participation by Older Women With Breast Cancer
Kemeny, M. M., Peterson, B. L., Kornblith, A. B., Muss, H. B., Wheeler, J., Levine, E., Bartlett, N., Fleming, G., & Cohen, H. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.124 · Cited by 465
Public Attitudes Toward Participation in Cancer Clinical Trials
Comis, R. L., Miller, J. D., Aldigé, C. R., Krebs, L., & Stoval, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.105 · Cited by 393
Peppercorn, J. M., Weeks, J. C., Cook, E. F., & Joffe, S. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15383-4 · Cited by 366
Hurria, A., Dale, W., Mooney, M., Rowland, J. H., Ballman, K. V., Cohen, H. J., Muss, H. B., Schilsky, R. L., Ferrell, B., Extermann, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0418 · Cited by 362
A systematic review and meta‐analysis of psychosocial interventions for couples coping with cancer
Badr, H., & Krebs, P. (2013) · Psycho-Oncology · doi:10.1002/pon.3200 · Cited by 330
Sustained Small Interfering RNA Delivery by Mesoporous Silicon Particles
Tanaka, T., Mangala, L. S., Vivas-Mejia, P. E., Nieves-Alicea, R., Mann, A. P., Mora, E., Han, H.-D., Shahzad, M. M. K., Liu, X., Bhavane, R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3931 · Cited by 316
Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier?
Yee, K. W. L., Pater, J. L., Pho, L., Zee, B., & Siu, L. L. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.044 · Cited by 304
Follicular Lymphoma in the United States: First Report of the National LymphoCare Study
Friedberg, J. W., Taylor, M. D., Cerhan, J. R., Flowers, C. R., Dillon, H., Farber, C. M., Rogers, E. S., Hainsworth, J. D., Wong, E. K., Vose, J. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1495 · Cited by 294
Patient Income Level and Cancer Clinical Trial Participation
Unger, J. M., Hershman, D. L., Albain, K. S., Moinpour, C. M., Petersen, J. A., Burg, K., & Crowley, J. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.4553 · Cited by 290
Patient-centric trials for therapeutic development in precision oncology
Biankin, A. V., Piantadosi, S., & Hollingsworth, S. J. (2015) · Nature · doi:10.1038/nature15819 · Cited by 282
Stewart, J. H., Bertoni, A. G., Staten, J. L., Levine, E. A., & Gross, C. P. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9500-y · Cited by 263
Unger, J. M., Hershman, D. L., Till, C., Minasian, L. M., Osarogiagbon, R. U., Fleury, M. E., & Vaidya, R. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djaa155 · Cited by 262
Adult cancer clinical trials that fail to complete: an epidemic?
Stensland, K. D., McBride, R. B., Latif, A., Wisnivesky, J., Hendricks, R., Roper, N., Boffetta, P., Hall, S. J., Oh, W. K., & Galsky, M. D. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju229 · Cited by 161
Fayter, D., McDaid, C., & Eastwood, A. (2007) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.12.013 · Cited by 112
Barriers and Challenges to Global Clinical Cancer Research
Seruga, B., Sadikov, A., Cazap, E. L., Delgado, L. B., Digumarti, R., Leighl, N. B., Meshref, M. M., Minami, H., Robinson, E., Yamaguchi, N. H., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0290 · Cited by 54
Maguire, R., Connaghan, J., Arber, A., Klepacz, N., Blyth, K. G., McPhelim, J., Murray, P., Rupani, H., Chauhan, A., Williams, P., et al. (2020) · Journal of Medical Internet Research · doi:10.2196/19180 · Cited by 38
Access Denied: Inequities in Clinical Trial Enrollment for Pancreatic Cancer
Eskander, M. F., Gil, L., Beal, E. W., Li, Y., Hamad, A., Oppong, B., Obeng-Gyasi, S., & Tsung, A. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10868-4 · Cited by 35
Metadata
- Authors
- Lara, P. N., Higdon, R., Lim, N., Kwan, K., Tanaka, M., Lau, D. H. M., Wun, T., Welborn, J., Meyers, F. J., Christensen, S., O’Donnell, R., Richman, C., Scudder, S. A., Tuscano, J., Gandara, D. R., & Lam, K. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-03-15
- Volume
- 19
- Issue
- 6
- Pages
- 1728-1733
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2226419169
- Cited by
- 588
- References
- 8
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.